Endologix Responds to Alleged Patent Infringement
October 13 2009 - 4:23PM
PR Newswire (US)
IRVINE, Calif., Oct. 13 /PRNewswire-FirstCall/ -- Endologix, Inc.
(NASDAQ: ELGX), developer of minimally invasive treatments for
aortic disorders, announced today that it has conducted further
evaluation of the patent infringement lawsuit filed against the
company last week by Cook Medical, and of the patents asserted in
the lawsuit. Based upon this evaluation, Endologix believes that
the alleged infringement is without merit and the company intends
to vigorously defend its position. John McDermott, Endologix
President and Chief Executive Officer, said, "We are pleased that
our initial evaluation of these claims, which Cook Medical waited
for years to assert, has already yielded support for numerous
promising defenses." About Endologix, Inc. Endologix, Inc. develops
and manufactures minimally invasive treatments for aortic
disorders. The Company's flagship product is the Powerlink® System,
which is an endovascular stent graft for the treatment of abdominal
aortic aneurysms (AAA). AAA is a weakening of the wall of the
aorta, the largest artery in the body, resulting in a balloon-like
enlargement. Once AAA develops, it continues to enlarge and, if
left untreated, becomes increasingly susceptible to rupture.
Additional information can be found on Endologix's Web site at
http://www.endologix.com/ Forward-Looking Statements Except for
historical information contained herein, this news release contains
forward-looking statements, specifically related to the claims of
alleged infringement. Please refer to the Company's Annual Report
on Form 10-K for the year ended December 31, 2008, and the
Company's other filings with the Securities and Exchange
Commission, for more detailed information regarding these risks and
other factors that may cause actual results to differ materially
from those expressed or implied. COMPANY CONTACT: INVESTOR
CONTACTS: ---------------- ------------------ Endologix, Inc. The
Ruth Group John McDermott, CEO Nick Laudico (646) 536-7030 (949)
595-7200 Zack Kubow (646) 536-7020 http://www.endologix.com/
DATASOURCE: Endologix, Inc. CONTACT: John McDermott, CEO,
Endologix, Inc., +1-949-595-7200; or Investors, Nick Laudico,
+1-646-536-7030, or Zack Kubow, +1-646-536-7020, both of The Ruth
Group Web Site: http://www.endologix.com/
Copyright